Breaking News

Gilead Acquires Phenex FXR Program

Comprises small molecule FXR agonists for the treatment of liver diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences has signed a definitive agreement to acquire Phenex Pharmaceuticals’ Farnesoid X Receptor (FXR) program of small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Phenex will receive an upfront payment plus development milestones that may potentially be worth as much as $470 million.   NASH is a common, serious chronic liver disease characterized by inflammation and excessive fat accumulation in the liver and may lead to prog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters